Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gilead Viread Rep Retraining Program Requested In FDA Warning Letter

Executive Summary

FDA is requesting that Gilead Sciences retrain its Viread sales reps following allegedly misleading claims of safety and efficacy for the anti-HIV agent cited in a July 29 warning letter to the company

You may also be interested in...



Exhibit Hall Promotion Compliance Is Improving, But Not Perfect, FDA Says

Manufacturers are becoming more compliant with FDA regulations regarding exhibit hall promotions, Division of Drug Marketing, Advertising & Communications Director Tom Abrams said

Exhibit Hall Promotion Compliance Is Improving, But Not Perfect, FDA Says

Manufacturers are becoming more compliant with FDA regulations regarding exhibit hall promotions, Division of Drug Marketing, Advertising & Communications Director Tom Abrams said

Booth Promotion Compliance Improving, FDA Says; Gilead Viread Cited At ICAAC

FDA's Division of Drug Marketing, Advertising & Communications believes that compliance with promotional regulations in the exhibit booth setting is improving

UsernamePublicRestriction

Register

ID1132115

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel